Obesity https://www.bioworld.com/rss en-us Ambrosia slurps up a $100M series B for its oral obesity drug pipeline http://www.bioworld.com/articles/730076 Thu, 02 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730076-ambrosia-slurps-up-a-100m-series-b-for-its-oral-obesity-drug-pipeline Pills, bottle, scale and-measuring tape Lilly’s Foundayo enters oral GLP-1 obesity market with speedy FDA nod http://www.bioworld.com/articles/729976 Wed, 01 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/729976-lillys-foundayo-enters-oral-glp-1-obesity-market-with-speedy-fda-nod Eli Lilly logo atop Lilly Biotechnology Center campus in San Diego, Calif. Credit: MichaelVi - stock.adobe.com China-developed triple incretin enters global diabetes race http://www.bioworld.com/articles/730088 Tue, 31 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/730088-china-developed-triple-incretin-enters-global-diabetes-race Illustration of glucose molecules in a bloodstream US FDA pondering next steps for CNPV http://www.bioworld.com/articles/729950 Mon, 30 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729950-us-fda-pondering-next-steps-for-cnpv Paper airplanes with red leading China-developed triple incretin enters global diabetes race http://www.bioworld.com/articles/729901 Thu, 26 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729901-china-developed-triple-incretin-enters-global-diabetes-race Illustration of glucose molecules in a bloodstream Wave stock shaken, analysts stirred by 007’s obesity phase I http://www.bioworld.com/articles/729900 Thu, 26 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729900-wave-stock-shaken-analysts-stirred-by-007s-obesity-phase-i Tape measure wrapped around feet on scale Study: GLP-1RAs associated with less risk of mental illness getting worse http://www.bioworld.com/articles/729743 Thu, 19 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729743-study-glp-1ras-associated-with-less-risk-of-mental-illness-getting-worse Mental illness art concept Triple crown: T2D purse for Lilly’s phase III retatrutide? http://www.bioworld.com/articles/729742 Thu, 19 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729742-triple-crown-t2d-purse-for-lillys-phase-iii-retatrutide Hand weight, sneakers, scale, measuring tape, apple, injector and glucose monitor Promise of exercise in a pill as Atrogi pivots from type 2 diabetes to obesity http://www.bioworld.com/articles/729562 Wed, 18 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729562-promise-of-exercise-in-a-pill-as-atrogi-pivots-from-type-2-diabetes-to-obesity Blue and green pill with barbell Structure’s oral GLP-1 data mark bullish year for obesity pills http://www.bioworld.com/articles/729549 Tue, 17 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729549-structures-oral-glp-1-data-mark-bullish-year-for-obesity-pills GLP-1 capsule Post-Emanate, Rhythm’s next Imcivree news aHO lot better? http://www.bioworld.com/articles/729545 Tue, 17 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729545-post-emanate-rhythms-next-imcivree-news-aho-lot-better Imcivree Credit: Rhythm Pharmaceuticals Inc. G2Gbio secures license deal, ₩20B investment from Samsung Epis http://www.bioworld.com/articles/729711 Tue, 17 Mar 2026 08:00:00 -0400 https://www.bioworld.com/articles/729711-g2gbio-secures-license-deal-20b-investment-from-samsung-epis G2gbio-Samsung-Bioepis deal signing From left: Epis Nexlab CEO Peter (Seong-won) Hong, Samsung Bioepis CEO Kim Kyung-ah and G2Gbio CEO Lee Hee-yong.  G2Gbio secures license deal, ₩20B investment from Samsung Epis http://www.bioworld.com/articles/729532 Mon, 16 Mar 2026 17:00:00 -0400 https://www.bioworld.com/articles/729532-g2gbio-secures-license-deal-20b-investment-from-samsung-epis G2gbio-Samsung-Bioepis deal signing From left: Epis Nexlab CEO Peter (Seong-won) Hong, Samsung Bioepis CEO Kim Kyung-ah and G2Gbio CEO Lee Hee-yong.  Zealand touts efficacy, safety for petrelintide phase II obesity trial http://www.bioworld.com/articles/729355 Fri, 06 Mar 2026 12:00:00 -0500 https://www.bioworld.com/articles/729355-zealand-touts-efficacy-safety-for-petrelintide-phase-ii-obesity-trial Man measuring waist Study: Weight regain after GLP-1s plateaus below starting weight http://www.bioworld.com/articles/729342 Thu, 05 Mar 2026 12:00:00 -0500 https://www.bioworld.com/articles/729342-study-weight-regain-after-glp-1s-plateaus-below-starting-weight Bathroom scale and injector pens Jiuyuan seeks approval of Wegovy biosimilar in China http://www.bioworld.com/articles/729318 Tue, 03 Mar 2026 12:00:00 -0500 https://www.bioworld.com/articles/729318-jiuyuan-seeks-approval-of-wegovy-biosimilar-in-china Jiuyuan seeks approval of Wegovy biosimilar in China http://www.bioworld.com/articles/729245 Thu, 26 Feb 2026 12:00:00 -0500 https://www.bioworld.com/articles/729245-jiuyuan-seeks-approval-of-wegovy-biosimilar-in-china FDA approves Allurion’s gastric balloon system http://www.bioworld.com/articles/729244 Thu, 26 Feb 2026 12:00:00 -0500 https://www.bioworld.com/articles/729244-fda-approves-allurions-gastric-balloon-system Allurion swallowable gastric balloon Allurion's swallowable gastric balloon features its Smart Capsule. Credit: Allurion Technologies Inc. Vivtex’s oral drug delivery approach draws Novo in $2.1B deal http://www.bioworld.com/articles/729200 Wed, 25 Feb 2026 12:00:00 -0500 https://www.bioworld.com/articles/729200-vivtexs-oral-drug-delivery-approach-draws-novo-in-21b-deal GI-ORIS-pic-Vivtex-2-25.jpg GI-ORIS, or “GI tract on a chip” screening system. Credit: Vivtex Corp. Ascletis raises $107M to advance oral GLP-1 to phase III trials http://www.bioworld.com/articles/729234 Tue, 24 Feb 2026 11:00:00 -0500 https://www.bioworld.com/articles/729234-ascletis-raises-107m-to-advance-oral-glp-1-to-phase-iii-trials 3D dollar sign Viking to push oral GLP-1/GIP drug into phase III obesity trial http://www.bioworld.com/articles/728847 Thu, 12 Feb 2026 12:00:00 -0500 https://www.bioworld.com/articles/728847-viking-to-push-oral-glp-1-gip-drug-into-phase-iii-obesity-trial Pills and bottle Ascletis raises $107M to advance oral GLP-1 to phase III trials http://www.bioworld.com/articles/728730 Wed, 11 Feb 2026 12:00:00 -0500 https://www.bioworld.com/articles/728730-ascletis-raises-107m-to-advance-oral-glp-1-to-phase-iii-trials 3D dollar sign Heart intervention device-maker Insight lands $143M SSE IPO http://www.bioworld.com/articles/728803 Tue, 10 Feb 2026 11:00:00 -0500 https://www.bioworld.com/articles/728803-heart-intervention-device-maker-insight-lands-143m-sse-ipo Insight Lifetech IPO ceremony Insight Lifetech bell-ringing ceremony at the Shanghai Stock Exchange Feb. 5, 2026. Credit: Insight Lifetech Co. Ltd. Heart intervention device-maker Insight lands $143M SSE IPO http://www.bioworld.com/articles/728662 Fri, 06 Feb 2026 12:00:00 -0500 https://www.bioworld.com/articles/728662-heart-intervention-device-maker-insight-lands-143m-sse-ipo Insight Lifetech IPO ceremony Insight Lifetech bell-ringing ceremony at the Shanghai Stock Exchange Feb. 5, 2026. Credit: Insight Lifetech Co. Ltd. China NMPA approves Sciwind’s GLP-1 injection for diabetes http://www.bioworld.com/articles/728623 Tue, 03 Feb 2026 12:00:00 -0500 https://www.bioworld.com/articles/728623-china-nmpa-approves-sciwinds-glp-1-injection-for-diabetes Pfizer's Metsera GLP-1 hits mark for once-monthly dosing http://www.bioworld.com/articles/728543 Tue, 03 Feb 2026 12:00:00 -0500 https://www.bioworld.com/articles/728543-pfizers-metsera-glp-1-hits-mark-for-once-monthly-dosing Person injecting medicine into abdomen China NMPA approves Sciwind’s GLP-1 injection for diabetes http://www.bioworld.com/articles/728531 Mon, 02 Feb 2026 12:00:00 -0500 https://www.bioworld.com/articles/728531-china-nmpa-approves-sciwinds-glp-1-injection-for-diabetes Fractyl’s Revita reduces post-GLP-1 weight regain 70% http://www.bioworld.com/articles/728273 Thu, 29 Jan 2026 11:00:00 -0500 https://www.bioworld.com/articles/728273-fractyls-revita-reduces-post-glp-1-weight-regain-70 Illustration of Revita DMR in intestine Revita duodenal mucosal resurfacing system. Credit: Fractyl Laboratories Inc. Corxel raises $287M series D round to advance oral GLP-1 http://www.bioworld.com/articles/728500 Tue, 27 Jan 2026 00:00:00 -0500 https://www.bioworld.com/articles/728500-corxel-raises-287m-series-d-round-to-advance-oral-glp-1 White tablet imprinted with dollar sign Corxel raises $287M series D round to advance oral GLP-1 http://www.bioworld.com/articles/728169 Fri, 23 Jan 2026 12:00:00 -0500 https://www.bioworld.com/articles/728169-corxel-raises-287m-series-d-round-to-advance-oral-glp-1 White tablet imprinted with dollar sign